Cargando…

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

BACKGROUND: Papillary renal cell carcinoma (pRCC) is associated with EGFR expression and activation of MET signaling pathway. A randomized multicenter parallel two-stage phase II trial of MET inhibitor tivantinib alone or in combination with EGFR inhibitor erlotinib was conducted in patients with pR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Twardowski, Przemyslaw W., Tangen, Catherine M., Wu, Xiwei, Plets, Melissa R., Plimack, Elizabeth R., Agarwal, Neeraj, Vogelzang, Nicholas J., Wang, Jinhui, Tao, Shu, Thompson, Ian M., Lara, Primo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179121/ https://www.ncbi.nlm.nih.gov/pubmed/30334014 http://dx.doi.org/10.3233/KCA-170018

Ejemplares similares

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
por: Tolaney, Sara M., et al.
Publicado: (2015)

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()
por: Zaman, Shadia, et al.
Publicado: (2015)

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017)

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1
por: Lu, Shuai, et al.
Publicado: (2015)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Development of Tivantinib as Treatment for Hepatocellular Carcinoma
por: Au, Jennifer, et al.
Publicado: (2013)

Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study
por: Luo, Guang-li, et al.
Publicado: (2022)

Tivantinib alleviates inflammatory diseases by directly targeting NLRP3
por: Huang, Yi, et al.
Publicado: (2023)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
por: Kuenzi, Brent M., et al.
Publicado: (2019)

The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis
por: Wang, Yubin, et al.
Publicado: (2023)

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
por: Puzanov, Igor, et al.
Publicado: (2014)

The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis
por: Zhang, Hao, et al.
Publicado: (2017)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
por: Xiang, Qingfeng, et al.
Publicado: (2015)

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
por: Kummar, Shivaani, et al.
Publicado: (2021)

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
por: Rimassa, Lorenza, et al.
Publicado: (2016)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer
por: Yamamoto, N, et al.
Publicado: (2013)

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
por: Okusaka, Takuji, et al.
Publicado: (2015)

A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling
por: Wu, Yukun, et al.
Publicado: (2019)

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)
por: Synold, Timothy W., et al.
Publicado: (2019)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model
por: Previdi, Sara, et al.
Publicado: (2013)

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
por: Monk, Paul, et al.
Publicado: (2018)

Transmission of the atypical/Nor98 scrapie agent to Suffolk sheep with VRQ/ARQ, ARQ/ARQ, and ARQ/ARR genotypes
por: Cassmann, Eric D., et al.
Publicado: (2021)

ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
por: Gao, Xudong, et al.
Publicado: (2019)

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2017)

Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
por: Sayegh, Nicolas, et al.
Publicado: (2023)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer
por: Wong, Risa L., et al.
Publicado: (2020)

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
por: Lath, Darren L., et al.
Publicado: (2018)

Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
por: Boxley, Peter, et al.
Publicado: (2020)

ARQ20 : arquitectura en la España del siglo XX /
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_s1r2qbi7hrk0fp0jj4vlktcc5q